MedPath

RUBIUS THERAPEUTICS

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

RTX-224 Monotherapy in Patients With Solid Tumors

Phase 1
Terminated
Conditions
Non Small Cell Lung Cancer
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Urothelial Carcinoma
TNBC - Triple-Negative Breast Cancer
Interventions
Drug: RTX-224
First Posted Date
2022-02-02
Last Posted Date
2022-12-09
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
7
Registration Number
NCT05219578
Locations
๐Ÿ‡บ๐Ÿ‡ธ

HonorHealth, Scottsdale, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco Health, San Francisco, California, United States

and more 2 locations

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Phase 1
Terminated
Conditions
Cervical Cancer
Head and Neck Cancer
Anal Cancer
Interventions
Drug: RTX-321
First Posted Date
2020-12-17
Last Posted Date
2022-12-08
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
9
Registration Number
NCT04672980
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Angeles Clinic & Research Institute, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 7 locations

RTX-240 Monotherapy and in Combination With Pembrolizumab

Phase 1
Terminated
Conditions
Solid Tumor, AML Adult
Interventions
Drug: RTX-240
Drug: Pembrolizumab
First Posted Date
2020-05-04
Last Posted Date
2022-12-13
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
69
Registration Number
NCT04372706
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Virginia Cancer Specialists, Fairfax, Virginia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sylvester Comprehensive Cancer Center/UMHC, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California San Diego, La Jolla, California, United States

and more 8 locations

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

Phase 1
Terminated
Conditions
Phenylketonurias
Interventions
Drug: RTX-134
First Posted Date
2019-10-01
Last Posted Date
2022-12-08
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
1
Registration Number
NCT04110496
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital Colorado, Aurora, Colorado, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath